Cardiovascular disease risk in women living with HIV.
Journal
Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
10
8
2022
Statut:
ppublish
Résumé
To synthesize current evidence on the impact of cardiovascular disease among women living with HIV (WLWH) with a particular focus on disease prevalence, mechanisms and prevention. HIV-related cardiovascular disease risk is 1.5-fold to 2-fold higher for women than for men. Mechanisms of enhanced risk are multifactorial and include reinforcing pathways between traditional risk factors, metabolic dysregulation, early reproductive aging and chronic immune activation. These pathways influence both the presentation of overt syndromes of myocardial infarction, stroke and heart failure, as well as subclinical disease, such as microvascular dysfunction and cardiac fibrosis. Cardiovascular disease, therefore, remains a consistent threat to healthy aging among WLWH. Although no specific prevention strategies exist, patient-centered risk mitigation approaches that are adaptable to the needs of aging individuals are essential to combat disparities in cardiovascular outcomes among WLWH. Further research into the optimal prevention approach for CVD among WLWH, particularly for women living in under-resourced health systems, is needed.
Identifiants
pubmed: 35938460
doi: 10.1097/COH.0000000000000756
pii: 01222929-202209000-00004
pmc: PMC9370828
mid: NIHMS1818902
doi:
Banques de données
ClinicalTrials.gov
['NCT02272946']
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
270-278Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL146267
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL123341
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI157882
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL147723
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007828
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506–512.
Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000; 11:41–46.
Freiberg MS, Chang CCH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614–622.
Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177–187.
Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis 2016; 214: (Suppl 2): S44–S50.
Losina E, Hyle EP, Borre ED, et al. Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in persons living with human immunodeficiency virus in the United States. Clin Infect Dis 2017; 65:1266–1271.
Alonso A, Barnes AE, Guest JL, et al. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc 2019; 8:e012241.
Quiros-Roldan E, Raffetti E, Focà E, et al. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care 2016; 28:1551–1558.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506–2512.
Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228–1230.
Womack JA, Chang CCH, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc 2014; 3:e001035.
Baldé A, Lang S, Wagner A, et al. Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: impact of gender and immune status. PloS One 2019; 14:e0210253.
Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol 2017; 2:155–162.
Crane HM, Nance RM, Whitney BM, et al. Centers for AIDS Research Network of Clinical Information Systems. Brief report: differences in types of myocardial infarctions among people aging with HIV. J Acquir Immune Defic Syndr 2021; 86:208–212.
Thygesen K. What's new in the Fourth Universal Definition of Myocardial infarction? Eur Heart J 2018; 39:3757–3758.
Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study. BMC Public Health 2021; 21:401.
Silverberg MJ, Lyass A, Hurley L, Ehrbar R. Trends in Myocardial Infarction Risk by HIV Status in Two US Healthcare Systems. CROI; 2022.
Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a U.S. Healthcare System. J Acquir Immune Defic Syndr 2012; 60:351–358.
Chow FC, Wilson MR, Wu K, et al. Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. AIDS 2018; 32:1125–1135.
Chen Y, Gao Y, Zhou Y, et al. Human immunodeficiency virus infection and incident heart failure: a meta-analysis of prospective studies. J Acquir Immune Defic Syndr 1999 2021; 87:741–749.
Go AS, Reynolds K, Avula HR, et al. Human immunodeficiency virus infection and variation in heart failure risk by age, sex, and ethnicity: the HIV HEART Study. Mayo Clin Proc 2022; 97:465–479.
Feinstein MJ, Steverson AB, Ning H, et al. Adjudicated heart failure in HIV-infected and uninfected men and women. J Am Heart Assoc 2018; 7:e009985.
Sliwa K, Carrington MJ, Becker A, et al. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33:866–874.
Freiberg MS, Chang CCH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol 2017; 2:536–546.
Janjua SA, Triant VA, Addison D, et al. HIV infection and heart failure outcomes in women. J Am Coll Cardiol 2017; 69:107–108.
Thompson-Paul AM, Palella FJ, Rayeed N, et al. Excess heart age in adult outpatients in routine HIV care. AIDS 2019; 33:1935–1942.
Frazier EL, Sutton MY, Tie Y, et al. Differences by sex in cardiovascular comorbid conditions among older adults (aged 50-64 or ≥65 years) receiving care for human immunodeficiency virus. Clin Infect Dis 2019; 69:2091–2100.
Bloomfield GS, Hogan JW, Keter A, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PloS One 2011; 6:e22288.
Gaziano TA, Abrahams-Gessel S, Gomez-Olive FX, et al. Cardiometabolic risk in a population of older adults with multiple co-morbidities in rural South Africa: the HAALSI (Health and Aging in Africa: longitudinal studies of INDEPTH communities) study. BMC Public Health 2017; 17:206.
Houle B, Gaziano TA, Angotti N, et al. Hypertension incidence among middle-aged and older adults: findings from a 5-year prospective study in rural South Africa. BMJ Open 2021; 11:e049621.
Ketelaar EJ, Vos AG, Godijk NG, et al. Ideal cardiovascular health index and its determinants in a rural South African Population. Glob Heart 2020; 15:76.
Hamooya BM, Mulenga LB, Masenga SK, et al. Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: prevalence and associated factors. Medicine (Baltimore) 2021; 100:e25236.
Kazooba P, Kasamba I, Mayanja BN, et al. Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy. Pan Afr Med J 2017; 27:40.
Godfrey C, Bremer A, Alba D, et al. Obesity and fat metabolism in human immunodeficiency virus-infected individuals: immunopathogenic mechanisms and clinical implications. J Infect Dis 2019; 220:420–431.
Conley LJ, Bush TJ, Rupert AW, et al. SUN (Study to Understand the Natural History of HIVAIDS in the Era of Effective Therapy) Investigators. Obesity is associated with greater inflammation and monocyte activation among HIV-infected adults receiving antiretroviral therapy. AIDS 2015; 29:2201–2207.
Lo J, Looby SED, Wei J, et al. Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS 2009; 23:2366–2370.
Srinivasa S, Thomas TS, Feldpausch MN, et al. Coronary vasculature and myocardial structure in HIV: physiologic insights from the renin-angiotensin-aldosterone system. J Clin Endocrinol Metab 2021; 106:3398–3412.
Koethe JR, Jenkins CA, Lau B, et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses 2016; 32:50–58.
Sharma A, Bynum SA, Schneider MF, et al. Changes in body mass index following HAART initiation among HIV-infected women in the Women's Interagency HIV Study. J AIDS Clin Res 2014; 5:1000323.
Kileel EM, Lo J, Malvestutto C, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: a propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus. Open Forum Infect Dis 2021; 8:ofab537.
McCann K, Shah S, Hindley L, et al. Implications of weight gain with newer antiretrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS 2021; 35:1657–1665.
Plum PE, Maes N, Sauvage AS, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis 2021; 21:910.
Appiah D, Schreiner PJ, Demerath EW, et al. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J Am Heart Assoc 2016; 5:e003769.
Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause N Y N 2012; 19:1081–1087.
Yoshida Y, Chen Z, Baudier RL, et al. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women. Diabetes Care 2021; 44:2564–2572.
Scherzer R, Greenblatt RM, Merhi ZO, et al. Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. Am J Obstet Gynecol 2017; 216:46.e1–46.e11.
Scherzer R, Bacchetti P, Messerlian G, et al. Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women. Am J Reprod Immunol 19892015; 73:273–284.
Looby SE, Fitch KV, Srinivasa S, et al. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS 2016; 30:383–393.
Zanni MV, Currier JS, Kantor A, et al. Correlates and timing of reproductive aging transitions in a global cohort of midlife women with human immunodeficiency virus: insights from the REPRIEVE Trial. J Infect Dis 2020; 222: (Suppl 1): S20–S30.
Bullington BW, Edmonds A, Ramirez C, et al. Premature and early menopause among US women with or at risk for HIV. Menopause 2022; 29:741–747.
Bahrami H, Budoff M, Haberlen SA, et al. Inflammatory markers associated with subclinical coronary artery disease: the Multicenter AIDS Cohort Study. J Am Heart Assoc 2016; 5:e003371.
Nordell AD, McKenna M, Borges ÁH, et al. INSIGHT SMART, ESPRIT Study Groups, SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
Hanna DB, Lin J, Post WS, et al. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. J Infect Dis 2017; 215:1352–1361.
McKibben RA, Margolick JB, Grinspoon S, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis 2015; 211:1219–1228.
Hoel H, Ueland T, Knudsen A, et al. Soluble markers of interleukin 1 activation as predictors of first-time myocardial infarction in HIV-infected individuals. J Infect Dis 2020; 221:506–509.
Wanjalla CN, Temu TM, Mashayekhi M, et al. IL-17A is associated with flow-mediated dilation and IL-4 with carotid plaque in persons with HIV. AIDS 2022; 36:963–973.
Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737–1746.
El-Far M, Hanna DB, Durand M, et al. Brief report: subclinical carotid artery atherosclerosis is associated with increased expression of peripheral blood IL-32 isoforms among women living with HIV. J Acquir Immune Defic Syndr 2021; 88:186–191.
Zanni MV, Awadalla M, Toribio M, et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus. J Infect Dis 2020; 221:1315–1320.
Lin J, Xue X, Anastos K, et al. Elevated microparticle tissue factor activity is associated with carotid artery plaque in hiv-infected women. J Acquir Immune Defic Syndr 2019; 81:36–43.
Temu TM, Wagoner J, Masyuko S, et al. Central obesity is a contributor to systemic inflammation and monocyte activation in virally suppressed adults with chronic HIV in Kenya. AIDS 2021; 35:1723–1731.
Siedner MJ, Zanni M, Tracy RP, et al. Increased systemic inflammation and gut permeability among women with treated HIV infection in rural Uganda. J Infect Dis 2018; 218:922–926.
Looby SE, Kantor A, Burdo TH, et al. Factors associated with systemic immune activation indices in a global primary cardiovascular disease prevention cohort of people with HIV on antiretroviral therapy. Clin Infect Dis 2022; ciac166[Epub ahead of print] doi: 10.1093/cid/ciac166.
doi: 10.1093/cid/ciac166
Santinelli L, Ceccarelli G, Borrazzo C, et al. Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. Biol Sex Differ 2020; 11:23.
Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 2014; 209: (Suppl 3): S86–S92.
Scully EP. Sex differences in HIV infection. Curr HIV/AIDS Rep 2018; 15:136–146.
Raghavan A, Rimmelin DE, Fitch KV, Zanni MV. Sex differences in select noncommunicable HIV-associated comorbidities: exploring the role of systemic immune activation/inflammation. Curr HIV/AIDS Rep 2017; 14:220–228.
Mathad JS, Gupte N, Balagopal A, et al. New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams. Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2016; 73:123–129.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16:626–638.
Shepherd R, Cheung AS, Pang K, et al. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol 2020; 11:604000.
Taneja V. Sex hormones determine immune response. Front Immunol 2018; 9:1931.
Mayneris-Perxachs J, Arnoriaga-Rodríguez M, Luque-Córdoba D, et al. Gut microbiota steroid sexual dimorphism and its impact on gonadal steroids: influences of obesity and menopausal status. Microbiome 2020; 8:136.
Zhao H, Chen J, Li X, et al. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota. FEBS Lett 2019; 593:2655–2664.
Peters BA, Xue X, Wang Z, et al. Menopausal status and observed differences in the gut microbiome in women with and without HIV infection. Menopause 2021; 28:491–501.
Soares C, Samara A, Yuyun MF, et al. Coronary artery calcification and plaque characteristics in people living with HIV: a systematic review and meta-analysis. J Am Heart Assoc 2021; 10:e019291.
Msoka TF, Van Guilder GP, van Furth M, et al. The effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: a systematic review and meta-analysis. Life Sci 2019; 235:116851.
Foldyna B, Fourman LT, Lu MT, et al. Sex differences in subclinical coronary atherosclerotic plaque among individuals with HIV on antiretroviral therapy. J Acquir Immune Defic Syndr 2018; 78:421–428.
Jeudy J, Patel P, George N, et al. Assessment of coronary inflammation in antiretroviral treated people with HIV infection and active HIV/hepatitis C virus co-infection. Lond Engl 2022; 36:399–407.
Longenecker CT, Bogorodskaya M, Margevicius S, et al. Sex modifies the association between HIV and coronary artery disease among older adults in Uganda. J Int AIDS Soc 2022; 25:e25868.
Siedner MJ, Bibangambah P, Kim J, et al. Treated HIV infection and progression of carotid atherosclerosis in rural Uganda: a prospective observational cohort study. J Am Heart Assoc 2021; 10:e019994.
Gdowski MA, Murthy VL, Doering M, et al. Association of isolated coronary microvascular dysfunction with mortality and major adverse cardiac events: a systematic review and meta-analysis of aggregate data. J Am Heart Assoc 2020; 9:e014954.
Kelshiker MA, Seligman H, Howard JP, et al. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J 2022; 43:1582–1593.
Iantorno M, Schär M, Soleimanifard S, et al. Coronary artery endothelial dysfunction is present in HIV-positive individuals without significant coronary artery disease. AIDS 2017; 31:1281–1289.
Iantorno M, Soleimanifard S, Schär M, et al. Regional coronary endothelial dysfunction is related to the degree of local epicardial fat in people with HIV. Atherosclerosis 2018; 278:7–14.
Leucker TM, Weiss RG, Schär M, et al. Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol. J Am Heart Assoc 2018; 7:e009996.
Knudsen A, Christensen TE, Ghotbi AA, et al. Normal myocardial flow reserve in HIV-infected patients on stable antiretroviral therapy. Medicine (Baltimore) 2015; 94:e1886.
Knudsen A, Thorsteinsson K, Christensen TE, et al. Cardiac microvascular dysfunction in women living with HIV is associated with cytomegalovirus immunoglobulin G. Open Forum Infect Dis 2018; 5:ofy205.
Ryom L, De Miguel R, Cotter AG, et al. Major revision version 11. 0 of the European AIDS Clinical Society Guidelines 2021. HIV Med 2022; [Epub ahead of print] doi: 10.1111/hiv.13268.
doi: 10.1111/hiv.13268
Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation 2019; 140:e98–e124.
Hatleberg CI, Ryom L, El-Sadr W, et al. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. J Int AIDS Soc 2018; 21:e25083.
Shahmanesh M, Schultze A, Burns F, et al. EuroSIDA in EuroCOORD. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS 2016; 30:2505–2518.
Kuniholm MH, Vásquez E, Appleton AA, et al. Cardiovascular risk score associations with frailty in men and women with or at risk for HIV. AIDS 2022; 36:237–347.
Erlandson KM, Fitch KV, McCallum SA, et al. Geographical differences in the self-reported functional impairment of people with HIV and associations with cardiometabolic risk. Clin Infect Dis 2022; ciac098[Epub ahead of print] doi: 10.1093/cid/ciac098.
doi: 10.1093/cid/ciac098
Grinspoon SK, Fitch KV, Overton ET, et al. REPRIEVE Investigators. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J 2019; 212:23–35.